Authorities File Bribery Charges Against Senior Officials Of Pharma Company And SFDA
This article was originally published in PharmAsia News
Chen Haifeng, head of China's State FDA's Center for Drug Evaluation and Gu Lijun, pharma company general manager, were taken to court for alleged bribery and corruption to the tune of RMB 1.3 million between 2004-2007 for fast drug registration approvals
You may also be interested in...
Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.